Characterisation of the influences of aspirin-acetylation and glycation on human plasma proteins

Journal of Proteomics

Volumn 114, Issue , 2015, Pages 125-135

  Finamore, Francesco ^a   Priego Capote, Feliciano ^b   Nolli, Severine ^c   Zufferey, Anne ^c   Fontana, Pierre ^c   Sanchez, Jean Charles ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b UNIVERSITY OF CÓRDOBA   (Spain)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Aspirin mediated acetylation; Human plasma; Label free quantitation; Mass spectrometry; Non enzymatic glycation

Indexed keywords

ACETYLSALICYLIC ACID; GLUCOSE; GLYCOSYLATED PROTEIN; PLASMA PROTEIN; GLYCOPROTEIN;

ACETYLATION; ARTICLE; CONFORMATIONAL TRANSITION; HUMAN; INCUBATION TIME; MASS SPECTROMETRY; PLASMA; PROTEIN ANALYSIS; PROTEIN GLYCOSYLATION; PROTEIN MODIFICATION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; WESTERN BLOTTING; AMINO ACID SEQUENCE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; GLYCOSYLATION; MALE; METABOLISM; MOLECULAR GENETICS; PROTEIN PROCESSING;

ACETYLATION; AMINO ACID SEQUENCE; ASPIRIN; BLOOD PROTEINS; GLUCOSE; GLYCOPROTEINS; GLYCOSYLATION; HUMANS; MALE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84913557656     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2014.11.005     Document Type: Article

References (49)

1. Deli G., Bosnyak E., Pusch G., Komoly S., Feher G. Diabetic neuropathies: diagnosis and management. Neuroendocrinology 2013, 98(4):267-280.
2. Badal S.S., Danesh F.R. New insights into molecular mechanisms of diabetic kidney disease. Am J Kidney Dis 2014, 63(2 Suppl. 2):S63-S83.
3. Cunha-Vaz J., Ribeiro L., Lobo C. Phenotypes and biomarkers of diabetic retinopathy. Prog Retin Eye Res 2014, 41:90-111.
4. Paneni F., Beckman J.A., Creager M.A., Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J 2013, 34(31):2436-2443.
5. Beckman J.A., Paneni F., Cosentino F., Creager M.A. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Eur Heart J 2013, 34(31):2444-2452.
6. Sensi M., Pricci F., Pugliese G., De Rossi M.G., Petrucci A.F., Cristina A., et al. Role of advanced glycation end-products (AGE) in late diabetic complications. Diabetes Res Clin Pract 1995, 28(1):9-17.
7. Mendez J.D., Xie J., Aguilar-Hernandez M., Mendez-Valenzuela V. Trends in advanced glycation end products research in diabetes mellitus and its complications. Mol Cell Biochem 2010, 341(1-2):33-41.
8. Ulrich P., Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res 2001, 56:1-21.
9. Singh V.P., Bali A., Singh N., Jaggi A.S. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol 2014, 18(1):1-14.
10. Baraka-Vidot J., Guerin-Dubourg A., Bourdon E., Rondeau P. Impaired drug-binding capacities of in vitro and in vivo glycated albumin. Biochimie 2012, 94(9):1960-1967.
11. Vetter S.W., Indurthi V.S. Moderate glycation of serum albumin affects folding, stability, and ligand binding. Clin Chim Acta 2011, 412(23-24):2105-2116.
12. Baraka-Vidot J., Guerin-Dubourg A., Dubois F., Payet B., Bourdon E., Rondeau P. New insights into deleterious impacts of in vivo glycation on albumin antioxidant activities. Biochim Biophys Acta 2014, 1830(6):3532-3541.
13. Rondeau P., Bourdon E. The glycation of albumin: structural and functional impacts. Biochimie 2011, 93(4):645-658.
14. Sun J.T., Shen Y., Lu A.K., Lu L., Shen W.F. Glycation of high-density lipoprotein in type 2 diabetes mellitus. Chin Med J (Engl) 2013, 126(21):4162-4165.
15. Titov V.N., Khokhlova N.V., Shiriaeva Iu K. Glucose, glycotoxins, and protein glycation products: the role in pathogenesis. Klin Med (Mosk) 2013, 91(3):15-24.
16. Kuzan A., Chwilkowska A., Kobielarz M., Pezowicz C., Gamian A. Glycation of extracellular matrix proteins and its role in atherosclerosis. Postepy Hig Med Dosw (Online) 2012, 66:804-809.
17. Park K.H., Jang W., Kim K.Y., Kim J.R., Cho K.H. Fructated apolipoprotein A-I showed severe structural modification and loss of beneficial functions in lipid-free and lipid-bound state with acceleration of atherosclerosis and senescence. Biochem Biophys Res Commun 2010, 392(3):295-300.
18. Hegab Z., Gibbons S., Neyses L., Mamas M.A. Role of advanced glycation end products in cardiovascular disease. World J Cardiol 2012, 4(4):90-102.
19. Li X.H., Du L.L., Cheng X.S., Jiang X., Zhang Y., Lv B.L., et al. Glycation exacerbates the neuronal toxicity of beta-amyloid. Cell Death Dis 2013, 4:e673.
20. Oliveira L.M., Gomes R.A., Yang D., Dennison S.R., Familia C., Lages A., et al. Insights into the molecular mechanism of protein native-like aggregation upon glycation. Biochim Biophys Acta 2013, 1834(6):1010-1022.
21. Harding J.J., Ganea E. Protection against glycation and similar post-translational modifications of proteins. Biochim Biophys Acta 2006, 1764(9):1436-1446.
22. Fang F., Lu Y., Ma D.L., Du T.T., Shao S.Y., Yu X.F. A meta-analysis of salicylates for type 2 diabetes mellitus. J Huazhong Univ Sci Technol Med Sci 2013, 33(1):1-14.
23. Hundal R.S., Petersen K.F., Mayerson A.B., Randhawa P.S., Inzucchi S., Shoelson S.E., et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002, 109(10):1321-1326.
24. Swamy M.S., Abraham E.C. Inhibition of lens crystallin glycation and high molecular weight aggregate formation by aspirin in vitro and in vivo. Invest Ophthalmol Vis Sci 1989, 30(6):1120-1126.
25. Nahomi R.B., Oya-Ito T., Nagaraj R.H. The combined effect of acetylation and glycation on the chaperone and anti-apoptotic functions of human alpha-crystallin. Biochim Biophys Acta 2013, 1832(1):195-203.
26. Hadley J., Malik N., Meek K. Collagen as a model system to investigate the use of aspirin as an inhibitor of protein glycation and crosslinking. Micron 2001, 32(3):307-315.
27. Urios P., Grigorova-Borsos A.M., Sternberg M. Aspirin inhibits the formation of pentosidine, a cross-linking advanced glycation end product, in collagen. Diabetes Res Clin Pract 2007, 77(2):337-340.
28. Bakhti M., Habibi-Rezaei M., Moosavi-Movahedi A.A., Khazaei M.R. Consequential alterations in haemoglobin structure upon glycation with fructose: prevention by acetylsalicylic acid. J Biochem 2007, 141(6):827-833.
29. Svensson J., Bergman A.C., Adamson U., Blomback M., Wallen H., Jorneskog G. Acetylation and glycation of fibrinogen in vitro occur at specific lysine residues in a concentration dependent manner: a mass spectrometric and isotope labeling study. Biochem Biophys Res Commun 2012, 421(2):335-342.
30. Yi T.N., Zhao H.Y., Zhang J.S., Shan H.Y., Meng X., Zhang J. Effect of aspirin on high glucose-induced senescence of endothelial cells. Chin Med J (Engl) 2009, 122(24):3055-3061.
31. Russo I., Viretto M., Barale C., Mattiello L., Doronzo G., Pagliarino A., et al. High glucose inhibits the aspirin-induced activation of the nitric oxide/cGMP/cGMP-dependent protein kinase pathway and does not affect the aspirin-induced inhibition of thromboxane synthesis in human platelets. Diabetes 2012, 61(11):2913-2921.
32. Ertugrul D.T., Tutal E., Yildiz M., Akin O., Yalcin A.A., Ure O.S., et al. Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus. J Clin Endocrinol Metab 2010, 95(6):2897-2901.
33. Finamore F., Priego-Capote F., Gluck F., Zufferey A., Fontana P., Sanchez J.C. Impact of high glucose concentration on aspirin-induced acetylation of human serum albumin: an in vitro study. EuPA Open Proteomics 2014, 3:100-113.
34. Gershoni J.M., Palade G.E. Electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to a positively charged membrane filter. Anal Biochem 1982, 124(2):396-405.
35. Priego-Capote F., Ramirez-Boo M., Finamore F., Gluck F., Sanchez J.C. Quantitative analysis of glycated proteins. J Proteome Res 2014, 13(2):336-347.
36. Zhang Q., Schepmoes A.A., Brock J.W., Wu S., Moore R.J., Purvine S.O., et al. Improved methods for the enrichment and analysis of glycated peptides. Anal Chem 2008, 80(24):9822-9829.
37. Gluck F., Hoogland C., Antinori P., Robin X., Nikitin F., Zufferey A., et al. EasyProt - an easy-to-use graphical platform for proteomics data analysis. J Proteomics 2012, 79C:146-160.
38. Borthwick G.M., Johnson A.S., Partington M., Burn J., Wilson R., Arthur H.M. Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism. FASEB J 2006, 20(12):2009-2016.
39. Needs C.J., Brooks P.M. Clinical pharmacokinetics of the salicylates. Clin Pharmacokinet 1985, 10(2):164-177.
40. Olsen J.V., Macek B., Lange O., Makarov A., Horning S., Mann M. Higher-energy C-trap dissociation for peptide modification analysis. Nat Methods 2007, 4(9):709-712.
41. Liyasova M.S., Schopfer L.M., Lockridge O. Reaction of human albumin with aspirin in vitro: mass spectrometric identification of acetylated lysines 199, 402, 519, and 545. Biochem Pharmacol 2010, 79(5):784-791.
42. Kisugi R., Kouzuma T., Yamamoto T., Akizuki S., Miyamoto H., Someya Y., et al. Structural and glycation site changes of albumin in diabetic patient with very high glycated albumin. Clin Chim Acta 2007, 382(1-2):59-64.
43. Ahmad S., Moinuddin, Ali A. Immunological studies on glycated human IgG. Life Sci 2012, 90(25-26):980-987.
44. Kaschak T., Boyd D., Yan B. Characterization of glycation in an IgG1 by capillary electrophoresis sodium dodecyl sulfate and mass spectrometry. Anal Biochem 2011, 417(2):256-263.
45. Nobecourt E., Tabet F., Lambert G., Puranik R., Bao S., Yan L., et al. Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I. Arterioscler Thromb Vasc Biol 2010, 30(4):766-772.
46. Lapolla A., Brioschi M., Banfi C., Tremoli E., Cosma C., Bonfante L., et al. Nonenzymatically glycated lipoprotein ApoA-I in plasma of diabetic and nephropathic patients. Ann N Y Acad Sci 2008, 1126:295-299.
47. Kurosaki Y., Tsukushi T., Munekata S., Akahoshi T., Moriya T., Ogawa Z. Semiquantitative analysis of apolipoprotein A-I modified by advanced glycation end products in diabetes mellitus. J Clin Lab Anal 2013, 27(3):231-236.
48. Gaillard O., Meillet D., Bordas-Fonfrede M., Khalil L., Galli J., Delattre J. Application of the time-resolved immunofluorometric assay to the study of C3 complement component glycation in vitro and in vivo. Eur J Clin Chem Clin Biochem 1993, 31(11):749-752.
49. Austin G.E., Mullins R.H., Morin L.G. Non-enzymic glycation of individual plasma proteins in normoglycemic and hyperglycemic patients. Clin Chem 1987, 33(12):2220-2224.